Licensing Opportunity: West Nile Virus Vaccines

 Licensing Opportunity:

West Nile Virus Vaccines

A mosquito biting a woman's hand. Credit: NIAID

West Nile virus (WNV) is considered a significant emerging disease over a considerable region of the United States. Usually associated with mild symptoms such as a low-grade fever or headache, WNV infection can cause hepatitis, meningitis, and encephalitis, leading to paralysis, coma, and even death for especially vulnerable populations, such as adults over the age of 60.

NIAID researchers have developed an attenuated, immunogenic viral vaccine for prevention of WNV infection. Two Phase I clinical trials showed the live, attenuated WNV vaccine to be safe, well-tolerated, and immunogenic in healthy adult volunteers. The vaccine virus may also be considered for use as a safe reagent for WNV diagnosis and surveillance.

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-357-2001-1.

Follow NIAID Tech Transfer on LinkedIn.